Posted 11/28/2023, 4:51:49 PM
Pfizer Trails GSK in Battle for RSV Vaccine Market Share
- Pfizer disappointed with its RSV vaccine market share versus GSK's vaccine
- GSK accounted for 2/3 of US RSV shots since September, helped by exclusive deal with CVS
- Pfizer CFO says they expected better performance and aim to gain more market share in 2024
- Both Pfizer and GSK shots approved in May for adults 60+; Pfizer also for pregnant women
- Pfizer beat Q3 expectations due to larger than expected overall RSV vaccine market